Why has US goverment given exemption to Indian pharmaceutical sector
The US granted a crucial exemption to India’s pharmaceutical industry from recent tariffs, recognizing the critical role of Indian generics in maintaining affordable healthcare. While initially a 50% tariff was imposed, the exemption protects the sector, preventing disruption to US drug access. Major Indian pharmaceutical players like Zydus Lifesciences, Dr. Reddy’s, Gland Pharma, and Biocon, heavily reliant on the US market, would be significantly impacted.